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Abstract
Background: Mutation of tumor suppressor gene, adenomatous polyposis coli (APC), is the primary molecular event in the
development of most intestinal carcinomas. Animal model with APC gene mutation is an effective tool for study of
preventive approaches against intestinal carcinomas. We aimed to evaluate the effect of Riccardin D, a macrocyclic
bisbibenzyl compound, as a chemopreventive agent against intestinal adenoma formation in APC
Min/+ mice.
Methods: APC
Min/+ mice were given Riccardin D by p.o. gavage for 7 weeks. Mice were sacrificed, and the number, size and
histopathology of intestinal polyps were examined under a microscope. We performed immunohistochemical staining,
western blotting, reverse transcriptase-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay
(ELISA) in intestinal polyps to investigate the mechanism of chemopreventive effect of Riccardin D.
Results: Riccardin D treatment resulted in a significant inhibition of intestinal adenoma formation, showing a reduction of
polyp number by 41.7%, 31.1% and 44.4%, respectively, in proximal, middle and distal portions of small intestine. The
activity of Riccardin D against polyp formation was more profound in colon, wherein Riccardin D decreased polyp number
by 79.3%. Size distribution analysis revealed a significant reduction in large-size polyps (2–3 mm) by 40.0%, 42.5% and
33.3%, respectively, in proximal, middle and distal portions of small intestine, and 77.8% in colon. Histopathological analysis
of the intestinal polyps revealed mostly hyperplastic morphology without obvious dysplasia in Riccardin D-treated mice.
Molecular analyses of the polyps suggested that the inhibitory effect of Riccardin D on intestinal adenoma formation was
associated with its abilities of reduction in cell proliferation, induction of apoptosis, antiangiogenesis, inhibition of the Wnt
signaling pathway and suppression of inflammatory mediators in polyps.
Conclusions: Our results suggested that Riccardin D exerts its chemopreventive effect against intestinal adenoma formation
through multiple mechanisms including anti-proliferative, apoptotic, anti-angiogenic and anti-inflammatory activity.
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Introduction
Colorectal cancer (CRC) is the second leading cause of cancer
morbidity and mortality worldwide. Most tumors arise sporadi-
cally (90%) and heritable cases constitute only 5 to 10% of all
CRC population [1–3]. The mutation of tumor suppressor gene,
adenomatous polyposis coli (APC), was found in all CRCs with
familial adenomatous polyposis (FAP), and in approximately 80%
of sporadic CRCs [4–6]. The normal function of APC protein is to
degrade b-catenin through the Wnt signaling transduction
pathway [6]. Dysregulation of the Wnt signaling pathway from
APC gene mutation results in increase of b-catenin expression in
nucleus. In the nucleus, the transcription factor, T cell factor/
lymphoid enhancer factor (TCF/LEF) will be transactivated by b-
catenin leading to an increased expression of genes that regulate
cell proliferation and apoptosis such as cyclin-D1 and c-Myc. The
APC gene mutation mouse (APC
Min/+) has an autosomal dominant
heterozygous nonsense mutation of the mouse APC gene at codon
850, homologous to the human germ line and somatic APC
mutations [7]. Thus, APC
Min/+ mouse has been well recognized as
the standard experimental model for the study of intestinal
carcinogenesis because it allows the tumors to develop spontane-
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geous for testing chemopreventive agents targeted against early-
stage tumorigenesis because scores of adenomas grow to a grossly
detectable size within a few months [8].
Macrocyclic bisbibenzyls are a special class of liverwort-derived
components that belong to the family of phenolic compounds.
Riccardin D, a macrocyclic bisbibenzyl, was isolated from the
liverwort plant Dumortiera hirsute (Fig. 1) [9]. Our previous studies
showed that Riccardin D could interfere with the formation of
biofilm in Candida albicans [10]. Recently, Riccardin D was
found to inhibit the proliferation of human leukemia cell lines
including HL60, K562 and its multidrug resistant (MDR)
counterpart K562/A02 cells. Riccardin D was shown to induce
apoptosis of leukemia cells through targeting DNA topoisomerase
II [11]. Riccardin D inhibited tumor angiogenesis in human lung
carcinoma H460 xenografts in mice without apparent toxicity to
animals [12]. Thus, Riccardin D may have a chemotherapeutic
and possibly chemopreventive effect on cancers. In this study, we
first evaluated the chemopreventive effects of Riccardin D on
spontaneous intestinal adenoma formation in APC
Min/+ mice. We
then investigated the molecular mechanism of Riccardin D on the
inhibition of intestinal adenoma formation. Our results provide
scientific evidence that supports Riccardin D as a potential




Riccardin D was isolated from the liverwort plant Dumortiera
hirsuta by our group and its structure was identified as reported
previously (Fig. 1) [9,11]. The purity of Riccardin D as measured
by high performance liquid chromatography (HPLC) was 98.6%.
Animal model and drug treatment protocol
Male APC
Min/+ mice obtained from The Jackson Laboratory
(Bar Harbor, USA) were crossed with wild-type C57BL/6 female
mice to generate APC
Min/+ mice [6,7,13]. A total of 20 female
APC
Min/+ mice (age, 4 wk) were randomly divided into two groups.
After one week acclimation, the two groups of 10 mice (5 wk) each
were given the control (5% amylum) and Riccardin D 80 mg/kg
by p.o. gavage daily (0.2 ml/10 g body weight) for 7 consecutive
weeks. Selection of Riccardin D dose was based on our previous
studies [12,14]. Animals were weighed weekly and checked daily
for any signs of illness. The research protocol was approved strictly
in accordance with the institutional guidelines of Animal Care and
Use Committee at Shandong University. The permit number was
SYXK(LU)20100418.
Quantification of macroscopic and microscopic intestinal
adenomas
Following sacrifice, small intestine and colon were removed,
sliced longitudinally, rinsed with saline and spread onto micro-
scope slides. Small intestine was divided by length into three equal
sections (proximal, middle, and distal segments) according to
previous reports [15–17]. Polyps on intestinal segments were
counted, and their sizes were measured with digital caliper under a
dissecting microscope. The intestines were subsequently embedded
in paraffin and stained with hematoxylin and eosin (H&E) for
microscopic examination.
Immunohistochemistry staining and quantification
Sections of 4 mm thickness were cut from formalin-fixed
intestinal polyps. After deparaffinization, antigen retrieval, endog-
enous peroxidase activity was blocked by incubation with 3%
hydrogen peroxide in methanol for 10 min. The sections were
then washed twice in phosphate-buffered saline (PBS, pH 7.4) for
5 min. Non-specific binding was blocked by incubation with 5%
bovine serum albumin for 20 min. After incubation with primary
antibodies, the sections were washed and treated with biotinylated
anti-immunoglobulin, washed, reacted with avidin-conjugated
horseradish peroxidase H complex, and incubated in diamino-
benzidine and hydrogen peroxide. The sections were rinsed in
distilled water, counterstained with hematoxylin, and mounted
[18]. The primary antibodies included anti-proliferating cell
nuclear antigen (PCNA) (2586, 1:100 dilution), anti-b-catenin
(9562, 1:100 dilution), anti-cyclin D1 (2922, 1:100 dilution), anti-
cyclooxygenase-2 (COX-2) (4842, 1:50 dilution, Cell Signaling)
and anti-vascular endothelial growth factor (VEGF) (sc7269, 1:100
dilution, Santa Cruz). For the subsequent reaction, SABC kit
(Bostar, China) was used according to manufacturer’s instruction.
Nuclear positivity of PCNA and cyclin D1 were quantified as
percentage of positive cells per analyzed area as described
previously [15]. The cytoplasmic and nuclear staining of b-
catenin, and cell membrane staining of COX-2 and VEGF were
quantified by scoring the intensity as 0 (no staining), +1 (very
weak), +2 (weak), +3 (moderate), and +4 (strong) at five randomly
selected fields at 4006magnification in each sample [15,16].
Apoptotic cells in intestinal polyps were identified by terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) staining using In Situ Cell Death Detection Kit (Roche,
Germany) [19]. Serial 4-mm sections were cut from formalin-fixed
intestinal polyps. The staining was performed according to
manufacturer’s instruction. The proportion of the TUNEL-
positive cells in at least three mice in one group was scored in
randomly chosen fields under a microscope [20].
CD34 immunohistochemical staining was performed to exam-
ine the angiogenesis in intestinal polyps. Sections of polyps
between 2–3 mm were used for analysis of angiogenesis. After
incubation with anti-CD34 (BA0532, Boster, China) at 4uC, the
sections were treated with biotinylated anti-immunoglobulin,
washed, reacted with avidin-conjugated horseradish peroxidase
H complex, and then incubated in diaminobenzidine and
hydrogen peroxide. The slides were rinsed in distilled water,
counterstained with hematoxylin, and mounted [21]. For
angiogenesis analysis, all morphological structures with a lumen
surrounded by CD34-positive endothelial cells were considered as
blood microvessels. Microvascular density (MVD) was calculated
by counting CD34 positive vessels as described previously [22].
Figure 1. The liverwort plant Dumortiera hirsuta and chemical
structure of Riccardin D.
doi:10.1371/journal.pone.0033243.g001
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Western blotting analysis was performed to evaluate the
expressions of cancer growth-related proteins in intestinal polyps.
Polyps were incubated with 50 ml RIPA lysis buffer at 4uC for
30 min and the lysates (30 mg of protein per lane) were
fractionated by SDS-PAGE. The proteins were electro-transferred
onto PVDF membranes and then the expressions were detected
using dilutions of the primary antibodies. The primary antibodies
included anti-NF-kB (sc-8008), anti-p-NF-kB Ser
536 (sc-33020),
anti-FGF-2 (sc79, Santa Cruz); anti-caspase-3 (9662), anti-caspase-
9 (9502), anti-cleaved PARP (9541), anti-Bcl-2 (2872), anti-Bax
(2772, Cell Signaling); anti-TNF-a (BA0131, Boster, China) and
anti-b-actin (ab6276, Abcam). The PVDF membranes were
washed in 0.05% Tween-20/TBS and then incubated with
horseradish peroxidase-conjugated secondary antibody. The
bound antibodies were visualized using an enhanced chemilumi-
nescence reagent (Millipore, USA) and quantified by densitometry
using ChemiDoc XRS+ image analyzer (Bio-Rad, USA). Densi-
tometric analyses of bands were adjusted with b-actin as loading
control [23]. Triplicate experiments with triplicate samples were
performed.
Reverse transcription-polymerase chain reaction
Reverse transcriptase-polymerase chain reaction (RT-PCR)
assay was used to analyze the expressions of COX-2 and TNF-a
in intestinal polyps [24]. Polyps were collected and total RNA was
extracted using the RNAeasy kit according to manufacturer’s
instruction (Sangon, China). RNA quality was confirmed by the
ratio of A260/A280 (1.8–2). The concentration of total RNA was
measured by detecting absorbance at 260 nm (A260). Then,
reverse transcription (RT) was carried out with 0.1 mg extracted
RNA using First Strand cDNA Synthesis Kit (Toyobo, Japan).
The following primers (Genecore Biotech, China) were used for
the specific amplification of COX-2: forward, 59-CCAGATGC-
TATCTTTGGGGA-39, reverse, 59-GCTCGGCTTCCAG-
TATTGAG-39; TNF-a: forward, 59-TGCCTATGTCT-
CAGCCTCTTC-39, reverse, 59-GAGGCCATTTGGGAACTT
CT-39). The expressions of b-actin (forward, 59-GACTACCT-
CATGAAGATCCT-39, reverse, 59-CCACATCTGCTG-
GAAGGTGG-39) were used as an internal control. The reaction
was performed at 37uC for 15 min, 98uC for 5 min; and 35 cycles
at 94uC for 30 s, 55.5uC for 30 s and 68uC for 1 min. PCR
products were specified on 2.5% agarose gels containing 0.5 mg/
ml of ethidium bromide and photographed under a UV
transilluminator. AlphaEaseFC software was used to analyze the
relative light intensities. Triplicate experiments with triplicate
samples were performed.
Assay for prostaglandin E2 levels
Small intestinal polyps and normal mucosa (100 mg) were
homogenized in 1 ml homogenization buffer (0.1 mol/L phos-
phate buffer, pH 7.4 containing 1 mmol/L EDTA and 10 mmol/
L indomethacin) with polytron-type homogenizer. The homoge-
nates were centrifuged at 14,000 g for 10 min at 4uC, and then the
supernatants were aliquoted and stored at 280uC for analysis. The
levels of prostaglandin E2 (PGE2) were measured using ELISA kit
(Cayman Chemical, USA) according to manufacturer’s protocol
[15].
Statistical analysis
Data were described as Mean 6 S.D. Comparison between
APC
Min/+ control and Riccardin D treatment group were
conducted by two-tailed Student’s t test using the SPSS/
Win13.0 software (SPSS, Inc., Chicago, Illinois). P value less than
0.05 was considered statistically significant.
Results
General observation
Riccardin D treatment was generally well tolerated by mice
during the long-term treatment. There is no apparent difference
between the treated and control mice in their body weight, the
function of liver and kidney, and peripheral blood elements count
(data not shown).




Min/+ mice, all polyps on intestines were histologically
identified as adenomas. Riccardin D treatment resulted in a strong
inhibition of intestinal adenoma formation in terms of decreased
polyp number, size, and appearance in small intestine and colon
(Fig. 2A, B). At age of 12 weeks, mice in control group developed
10.8, 11.3, and 11.2 polyps on average in proximal, middle, and
distal portions of small intestine, respectively. As shown in Fig. 2C,
the number of polyps in Riccardin D-treated mice were decreased
by 41.7% (p,0.001), 31.1% (p,0.001), and 44.4% (p,0.001),
respectively (Table 1). Size distribution analysis of polyps in small
intestine showed differential Riccardin D efficacy depending on
intestinal segment and polyp size (Table 2). Riccardin D reduced
number of ,1 mm size polyps by 35.3% (p,0.001) in proximal,
31.6% (p,0.001) in middle, and 37.3% (p,0.001) in distal
segments; 1 to 2 mm size polyps by 50.0% (p,0.001) in proximal,
25.0% (p=0.015) in middle, and 41.2% (p,0.001) in distal
segments ; and 2 to 3 mm size polyps by 40.0% (p=0.004) in
proximal, 42.5% (p,0.001) in middle, and 33.3% (p=0.005) in
distal segments (Fig. 2D). Bigger-size polyps (.3 mm) were not
observed in small intestines (Table 2).
Most prominent Riccardin D effect was observed on inhibition
of polyp number and size in colon. Riccardin D strongly decreased
number of colonic polyps by 80.6% (p,0.001, Fig. 2E, Table 1).
Size distribution analysis of colonic polyps showed a strong
decrease in ,1 mm (66.7%, p=0.051), 1 to 2 mm (70.8%,
p=0.004), 2 to 3 mm (77.8%, p,0.001) and in .3 mm (85.3%,
p,0.001) size polyps in Riccardin D-treated mice compared with
control (Fig. 2F).
Histological analysis of the intestinal polyps in control mice
revealed well formed tubular adenomatous polyps with low grade
dysplasia and focal high grade dysplasia in some large polyps
(Fig. 2G-b, 2G-c). In Riccardin D-treated mice, the polypoid area
in mucosa of intestines mostly showed hyperplastic morphology
without obvious dysplasia (Fig. 2G-e, 2G-f).
Decrease of b-catenin and cyclin D1 expression in
intestinal polyps
To investigate whether Riccardin D affected the Wnt signaling
pathway, we examined two of its main downstream targets, b-
catenin and cyclin D1. As shown in Fig. 3, Riccardin D treatment
resulted in a strong decrease of these molecules. Quantification of
the immunohistochemistry staining indicated the decrease of
nuclear b-catenin positivity by 66.7% (p,0.001), 60.0%
(p,0.001), and 61.9% (p,0.001; Fig. 3A) and cyclin D1-positive
cells by 46.7% (p,0.001), 54.3% (p,0.001) and 51.4% (p,0.001;
Fig. 3B) in polyps from proximal, middle, and distal portions of
small intestine, respectively, and in colon the inhibition rates of b-
catenin and cyclin D1 were 68.2% (p,0.001) and 50.7%
(p,0.001; Fig. 3A and B), respectively.
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33243Figure 2. Riccardin D prevented spontaneous intestinal polyposis in APC
Min/+ mice. (A and B): Representative pictures of distal small
intestinal and colon polyps; (C): The number of polyps per mouse in different parts of small intestines; (D): The size distribution of polyps in different
part of small intestines; (E): The number of polyps per mouse in colons; (F): The size distribution of polyps in colons. *, p,0.001; #,p ,0.01; $, p,0.05
versus control. (G): Histological analysis of intestinal polyps. Sections of small intestine and colon from control or Riccardin D-treated mice were
stained with hematoxylin and eosin (H&E) and analyzed under microscopy. a, Normal histology of small intestinal mucosa (1006). b, Small intestine of
control mice showed an area of villus effacement and formation of a polyp with dysplastic glands. The central part of the polyp showed surface
erosion and necrosis (406). c, Riccardin D-treated small intestine showed an area of epithelial hyperplasia without obvious dysplasia. The villus
architecture in polypoid area is well preserved (406). d, Normal histology of colonic mucosa (1006). e, Colon from control mice showed a large
pedunculated tubular adenoma (406). f, Colon in mucosa of Riccardin D-treated mice showed well preserved crypt architecture with normal surface
maturation. The surface epithelium showed minimal evidence of hyperplasia (406).
doi:10.1371/journal.pone.0033243.g002
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factors
Western blotting analysis showed that the expression and
activity of NF-kB were highly elevated in intestinal polyps of
APC
Min/+ mice. Riccardin D significantly decreased NF-kB
expression. As shown in Fig. 4A, the level of total NF-kB p65
protein in small intestinal polyps was strongly decreased by 66.2%
(p,0.001) of control. Further analysis of p-NF-kB Ser
536, the
active form of NF-kB, was markedly decreased by 73.2%
(p,0.001, Fig. 4A, bottom) of control.
We then examined the inhibitory effect of Riccardin D on the
expressions of TNF-a, COX-2 and PGE2 in intestinal polyps. As
shown in Fig. 4B, the level of TNF-a in intestinal polyp was
significantly decreased by Riccardin D as detected by western
blotting assay. Fig. 4C showed a strong COX-2 immunoreactivity
in intestinal polyps, which was markedly decreased by Riccardin
D. Quantification of the immunostained cells showed that
Riccardin D significantly decreased COX-2 immunoreactivity by
38.9% (p,0.001) in proximal, 55.6% (p,0.001) in middle, 52.6%
(p,0.001) in distal, and 44.4% (p,0.001) in polyps of small
intestine and colon (Fig. 4C, right).
The inhibitory effect of Riccardin D on TNF-a and COX-2
expression was further evidenced by RT-PCR analysis of small
intestinal polyps. As shown in Fig. 4D, the mRNA levels of TNF-a
and COX-2 were significantly decreased by 35.4% (p,0.01) and
54.5% (p,0.001) of control, respectively.
We measured the content of PGE2, which is an important
downstream product of COX-2, in intestinal polyps by ELISA
analysis. PGE2 levels in small intestinal polyps were elevated (3.5-
fold) compared with those in wild-type small intestinal tissue (data
not shown). Riccardin D markedly decreased PGE2 by 50.0%
(p,0.001; Fig. 4E), implying that the activity of COX-2 was
suppressed.
Riccardin D prevents proliferation of intestinal polyps
and triggers apoptosis via a caspase-dependent pathway
To assess whether Riccardin D efficacy is associated with its
anti-proliferative and pro-apoptotic effects, we examined the
expressions of PCNA, TUNEL and apoptotic proteins in intestinal
polyps. Microscopic examination of tissue sections showed a
decrease in PCNA (Fig. 5A) and an increase in TUNEL (Fig. 5B)
in polyps from Riccardin D-treated mice compared with those
from control mice. Quantification of PCNA staining showed
65.5% (p,0.001), 62.2% (p,0.001), 65.1% (p,0.001) and 67.0%
(p,0.001) reduction in proximal, middle, distal portions of small
intestine and colon polyps by Riccardin D. Quantitative data
showed that Riccardin D treatment resulted in increases of
TUNEL-positive cells in intestinal polyps by 51.9% (p,0.001) in
proximal, 57.9% (p,0.001) in middle, and 48.2% (p,0.001) in
distal portions of small intestine and 54.1% (p,0.001) in polyps of
colon (Fig. 5B).
Western blotting analysis indicated that Riccardin D could
activate the caspase cascade pathway as demonstrated by increases
of caspase-9, caspase-3 and cleaved PARP. As shown in Fig. 5C,
the levels of caspase-3, caspase-9 and cleaved PARP in small
intestinal polyps were significantly increased in Riccardin D-
treated mice. The increases of caspase-3, caspase-9 and cleaved
PARP were 75.0% (p,0.001), 70.9% (p,0.001), and 50.9%
(p,0.001) of control, respectively. Further analysis of proapoptotic
protein Bax and antiapoptotic protein Bcl-2 showed strong
increases of Bax activation and decreases of Bcl-2 expression
(Fig. 5D). These results indicated that the induction of apoptosis by
Riccardin D might be involved in the inhibition of intestinal
adenoma formation in APC
Min/+ mice.
Riccardin D decreases angiogenesis in intestinal polyps
We studied whether the inhibition of adenoma formation by
Riccardin D was associated with its ability of antiangiogenesis. We
first examined the microvessel density (MVD) in intestinal polyps
of 2–3 mm size by CD34 immunohistochemical staining assay.
The expressions of angiogenesis activators VEGF and FGF-2 in
these intestinal polyps were then evaluated by western blotting
analysis. As shown in Fig. 6A, the count of MVD in polyps from
proximal, middle and distal part of intestinal and colon of
Riccardin D-treated mice was significantly decreased by 49.2%
(p,0.001), 47.0% (p,0.001), 48.6% (p,0.001), and 44.2%
(p,0.001), respectively, compared with those from control mice.
The examination of VEGF by immunohistochemistry showed that
the intensity of immunoreactivity in intestinal polyps was
significantly decreased in Riccardin D-treated mice (Fig. 6B).
Quantitative data showed that Riccardin D decreases VEGF
immunoreactivity scores in polyps by 57.1% (p,0.001) in
Table 1. The number of polyps per mouse in different parts
of small intestine and colon.





Control 10.861.7 11.361.6 11.262.2 6.262.8






a, different parts of small intestine;
*, p,0.001 versus control.
doi:10.1371/journal.pone.0033243.t001





(mm) Control Riccardin D Control Riccardin D Control Riccardin D Control Riccardin D
,1.0 4.260.6 2.660.7 4.660.7 3.360.8 4.260.6 2.661.0 1.060.9 0.360.5
1.0–2.0 4.060.8 2.060.5 3.060.7 2.360.5 4.260.6 2.560.5 1.861.2 0.460.5
2.0–3.0 2.460.7 1.560.5 3.760.8 2.260.6 1.860.4 1.260.4 1.860.8 0.460.5
.3 . 0 ------1 . 2 60.4 0.260.4
a, different parts of small intestine.
doi:10.1371/journal.pone.0033243.t002
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portions of small intestine, and 52.6% (p,0.001) in colon (Fig. 6B)
of control. Fig. 7C showed the expression of FGF-2 in intestinal
polyps as estimated by western blotting analysis. Quantitative data
revealed that Riccardin D decreased FGF-2 expression by 53.4%
(p,0.001) in small intestine and 61.8% (p,0.001) in colon of
control. These results suggested that Riccardin D might target
angiogenesis during the progression of intestinal adenoma
formation. Importantly, the antiangiogenic effect of Riccardin D
was specific and limited to polyps, because we did not observe
considerable changes in the expression of these angiogenic factors
in normal crypt-villus regions in intestine of control and Riccardin
D-treated APC
Min/+ or wild-type C57BL/6 mice (data not shown).
Discussion
This study demonstrated that administration of Riccardin D
leads to the chemoprevention of intestinal adenoma formation in
APC
Min/+ mice, a genetically predisposed animal model of human
familial adenomatous polyposis (FAP) [25]. The key findings of
this study include: (a) Riccardin D significantly reduced the
number as well as the growth of intestinal polyps and prominently
decreased the incidence of larger colonic polyps in APC
Min/+ mice;
(b) the inhibitory effect of Riccardin D was associated with a
decrease of growth and an increase of apoptosis in intestinal
polyps; (c) Riccardin D decreased the chronic inflammation and
modulated cytokines in intestinal polyps in favor of its inhibition of
polyp growth; and (d) Riccardin D inhibited angiogenesis as
evidenced by the decrease of MVD, VEGF and FGF-2 in
intestinal polyps. Riccardin D did not show apparent toxicity to
animals during the long-term treatment. These results suggested
that Riccardin D could be a potential chemopreventive regimen
for intestinal cancers derived from APC gene mutation. The
proposed molecular pathways for the inhibitory effects of
Riccardin D were summarized in Fig. 7.
In our previous studies, we had reported a group of macrocyclic
bisbibenzyls, including Riccardin D, Plagiochin E and Marchantin
C, which belong to the family of phenolic compounds [26]. These
compounds possess a wide range of biological activities, such as
anti-bacterial, anti-oxidation and cytotoxicity as well as inhibitory
effects on cyclooxygenase, calmodulin and 5-lipoxygenase [27,28].
Among them, Riccardin D has become the most promising
therapeutic agent, for its high efficacy against human cancers with
lower toxicity to animals. The structure-activity analysis suggested
that the activity of these compounds might associate with the
number and binding position of phenolic hydrogen [9]. We had
studied the pharmacokinetics of Plagiochin E after oral (80 mg/kg)
administration in rats [14]. The results showed a good
bioavailability (10.6%) and a higher level of plasma concentration
of Plagiochin E after observation (313.5 ng/ml) [14]. In this
study, Riccardin D has the very similar chemical structure to
Plagiochin E with three phenolic hydroxyl groups in double
biphenyl bonds. We hypothesized that Riccardin D might possess
the similar profile of pharmacokinetics given orally; thus, we
dosed our animals with Riccardin D based on the phar-
macokinetic calculation of Plagiochin E. The dose of Riccardin
D used in this study showed high efficacy in the inhibition of
intestinal adenoma formation in APC
Min/+ mice without obvious
Figure 3. Riccardin D decreased expression of b-catenin and cyclin D1 in intestinal polyps. Intestinal sections were processed for b-
catenin and cyclin D1 immunohistochemistry staining. Intestinal sections of control and Riccardin D-treated mice showed brown-colored PCNA-
positive (A) and cyclin D1-positive cells (B) in polyps on small intestines and colons (4006). Bar represents the mean 6 S.D of six animals. *, p,0.001
versus control.
doi:10.1371/journal.pone.0033243.g003
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Riccardin D are needed before it is being considered for clinical
application.
The adenomatous polyposis coli multiple intestinal neoplasia
(APC
Min/+) mouse model represents the phenotypes of FAP, a
hereditary CRC predisposition syndrome in humans [25,29].
Patients with FAP develop multiple adenomas in the intestine,
which eventually lead to the development of malignant adeno-
carcinomas through activation of the Wnt signaling pathway [6–
8]. Cancer epidemic analysis showed that APC mutations were also
found in approximately 80% of sporadic colorectal tumors. APC
gene acts as a central gatekeeper protein in colorectal tumorigen-
esis [30]. Molecular studies suggested that the mutation of APC
gene causes b-catenin to disassociate from cell membrane, and to
migrate into nucleus. In the nucleus, b-catenin promotes the
transcription of target genes that in turn leads to uncontrolled cell
proliferation [31]. As a consequence, the cells affected will show a
high expression of proliferation markers such as PCNA and cyclin
D1 [6–8]. These biomarkers are most important downstream
targets for the Wnt signaling pathway and have been previously
shown to be highly expressed in the adenomas of APC
Min/+ mice
[6–8]. Thus, the relevance of APC
Min/+ mouse model and the
development of intestinal cancers in human were well recognized.
In this study, Riccardin D was found to reduce the expressions
of b-catenin, PCNA and cyclin D1 in intestinal adenoma, imply-
ing that the Wnt signaling pathway might be inhibited by
Riccardin D.
Apoptosis, defined as programmed cell death, is an evolutionary
conserved mechanism to balance cell proliferation essential for
maintenance of tissue homeostasis. Tumor cells are characterized
Figure 4. Riccardin D suppressed inflammation by decreasing COX-2 and NF-kB in intestinal polyps. (A): The inhibition of NF-kB and p-
NF-kB Ser
536 in intestinal polyps of Riccardin D-treated mice (n=3). (B): The inhibition of TNF-a in intestinal polyps of Riccardin D-treated mice (n=3).
(C): The inhibition of COX-2 expression in polyps on small intestines and colons of Riccardin D-treated mice. The bars indicate mean 6 S.D. (n=6). (D):
The decrease of COX-2 mRNA in polyps on small intestines as estimated by RT-PCR analysis (n=3). (E): The content of PGE2 in small intestinal polyps
was decreased in Riccardin D-treated mice as measured by ELISA analysis. The bars indicate mean 6 S.D. (n=3). *, p,0.001 versus control.
doi:10.1371/journal.pone.0033243.g004
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apoptosis. Excessive adenoma growth and insufficient apoptosis
are often associated with CRC development and progression, and
the agents modulating them have immense potential in CRC
chemoprevention or therapeutic intervention [32]. In this study,
Riccardin D prevented adenoma growth and induced apoptosis of
intestinal polyps by decreasing of PCNA and cyclin D1 in APC
Min/
+ mice. Furthermore, Riccardin D induced the apoptosis of
intestinal polyps by increasing of TUNEL-positive cells and
activated caspase-dependent pathway. This apoptotic effect of
Riccardin D in intestinal polyps might be part of the underlying
mechanisms for the significant decrease in the number as well as
the size of polyps in APC
Min/+ mice. Importantly, induction of
apoptosis and inhibition of adenoma growth by Riccardin D were
specific to adenomas without obvious effect on normal crypt-villus
regions.
Enormous studies suggest that chronic inflammation plays an
important role in intestinal tumorigenesis. Chronic inflammatory
bowel disease accounts for about two thirds of the sporadic
colorectal cancers [33]. Increase of inflammatory stress has been
reported to be correlated with the development of intestinal
polyposis in APC
Min/+ mice. Inactivation of APC gene in epithelial
and stromal cells in human intestine and colon is associated with
the NF-kB-COX-2 interaction [34]. In this interaction, the
transcription factor kappa B (NF-kB), a proinflammatory tran-
scription factor, acts as ‘first responder’ to various types of cellular
stress such as free radicals, and pro-inflammatory cytokines such as
TNF-a and bacterial components. NF-kB-p65, the active form of
Figure 5. Riccardin D decreased proliferation and induced apoptosis in intestinal polyps. (A and B): Intestinal polyps of control and
Riccardin D-treated mice showed brown-colored PCNA-positive (A) and TUNEL-positive (B) cells in polyps (4006). Quantitative data for proliferation
and apoptosis were determined as number of PCNA-positive, TUNEL-positive cells6100/total number of cells, respectively. The bars represent mean
6 S.D. of six animals. *, p,0.001 versus control. (C and D): The alteration of apoptotic proteins in polyps on small intestine as estimated by western
blotting analysis. (C): The levels of caspase-9, caspase-3 and cleaved PARP in intestinal polyps were increased by Riccardin D (n=3). (D): Bcl-2 was
decreased and Bax was increased in intestinal polyps in Riccardin D-treated mice (n=3).
doi:10.1371/journal.pone.0033243.g005
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33243Figure 6. Riccardin D inhibited angiogenesis in intestinal polyps. (A): Immunohistochemical staining of CD34 for analysis of microvessel
density (MVD) in polyps of 2–3 mm on small intestines and colons. MVD in polyps of different intestine segments was significantly inhibited by
Riccardin D. (B): The expression of VEGF in polyps was inhibited by Riccardin D as estimated by immunohistochemical staining assay. The bars
represent mean 6 S.D. of six animals. *, p,0.001 versus control. (C): Riccardin D decreased the expression of FGF-2 in intestinal polyps as estimated
by western blotting assay (n=3).
doi:10.1371/journal.pone.0033243.g006
Figure 7. Summary for the pathways inhibited by Riccardin D in APC
Min/+ mice intestinal polyps.
doi:10.1371/journal.pone.0033243.g007
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[1,2] and activate MMP-9, VEGF and cyclin D1 which have the
NF-kB binding site in their transcription promoters [35].
Accumulation of NF-kB further increases the activation of
COX-2 and the Wnt signaling pathway that is regulated by APC
gene. COX-2, an immediate-early growth response gene product,
is normally absent or expressed at very low levels in most cells but
highly inducible in response to inflammatory cytokines, growth
factors, and tumor promoters [1,32]. One of the major
arachidonic acid metabolites by COX-2 that is elevated in FAP
patients is PGE2, implicating its major role in the formation of
polyps on intestines [36]. PGE2 strongly stimulates the prolifer-
ation of intestinal polyps and suppresses apoptotic cell death of
epithelial cells, leading to the expansion of polyps [37]. PGE2 also
stimulates the polyps to expansion through increases of angiogen-
esis and provide a route for invasion and metastasis [38].
Therefore, NF-kB-COX-2 mediated inflammation displays the
central roles in the stimulation of polyp growth on intestines. In
this study, the NF-kB-COX-2 interaction was inhibited and its
downstream product PGE2 was decreased by Riccardin D. Thus,
the anti-inflammation mechanisms of Riccardin D likely played an
important role in the observed suppression of polyps on intestines
in APC
Min/+ mice.
Another important observation was that Riccardin D strikingly
decreased the number of polyps that were larger in size (2–3 mm),
suggesting that Riccardin D inhibited the progression of excessive
proliferation of abnormal cells into polyps and also smaller polyps
into larger ones. In intestinal polyps, angiogenesis is triggered
when tumors grow beyond a minimal size (,2 mm) [4,15]. In this
progression, VEGF and FGF-2 are important downstream targets
of b-catenin that lead to endothelial cell proliferation to form
vessels that support intestinal polyp growth and expansion [39,40].
Riccardin D strongly inhibited the expressions of VEGF and FGF-
2 and reduced the newly formed microvessel density in intestinal
polyps. Therefore, the angiopreventive effect of Riccardin D could
be an additional mechanism for its chemoprevention of intestinal
adenoma formation.
In conclusion, our results showed antiproliferative, apoptotic,
anti-inflammatory and anti-angiogenic effects of Riccardin D in
intestinal polyps, which collectively contribute to its inhibition on
spontaneous intestinal adenoma formation in APC
Min/+ mice. Our
observation suggests that Riccardin D could be a promising
regimen in chemoprevention against intestinal tumorigenesis.
Acknowledgments
This work was supported by the Department of Pathology and Laboratory
Medicine, University of Calgary and Calgary Laboratory Services,
Canada.
Author Contributions
Conceived and designed the experiments: HPL HXL XJQ. Performed the
experiments: HPL. Analyzed the data: HPL SXC DFS YW CRZ. Wrote
the paper: HPL ZHG XJQ.
References
1. Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ (2009)
Expression of COX-2, NF-kB-p65, NF-kB-p50 and IKKa in malignant and
adjacent normal human colorectal tissue. Br J Cancer 101: 106–115.
2. Terzic ´ J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon
cancer. Gastroenterology 138: 2101–2114.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, et al. (2010)
Colorectal cancer. Lancet 375: 1030–1047.
4. Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, et al. (1991) Mutations of
chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253:
665–669.
5. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, et al. (1991)
Identification and characterization of the familial adenomatous polyposis coli
gene. Cell 66: 589–600.
6. Kwong LN, Dove WF (2009) APC and its modifiers in colon cancer. Adv Exp
Med Biol 656: 85–106.
7. McCart AE, Vickaryous NK, Silver A (2008) Apc mice: models, modifiers and
mutants. Pathol Res Pract 204: 479–490.
8. Yamada Y, Mori H (2007) Multistep carcinogenesis of the colon in Apc
Min/+
mouse. Cancer Sci 98: 6–10.
9. Lu ZQ, Fan PH, Ji M, Lou HX (2006) Terpenoids and bisbibenzyls from
Chinese liverworts Conocephalum conicum and Dumortiera hirsute. J Asian
Nat Prod Res 8: 187–192.
10. Cheng A, Sun L, Wu X, Lou H (2009) The inhibitory effect of a macrocyclic
bisbibenzyl riccardin D on the biofilms of Candida albicans. Biol Pharm Bull 32:
1417–1421.
11. Xue X, Qu XJ, Gao ZH, Sun CC, Liu HP, et al. (2010) Riccardin D, a novel
macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting
DNA topoisomerase II. Invest New Drugsdoi: 10.1007/s10637-010-9554-8.
12. Sun CC, Zhang YS, Xue X, Cheng YN, Liu HP, et al. (2011) Inhibition of
angiogenesis involves in anticancer activity of riccardin D, a macrocyclic
bisbibenzyl, in human lung carcinoma. Eur J Pharmacol 667: 136–143.
13. Guillen-Ahlers H, Suckow MA, Castellino FJ, Ploplis VA (2010) Fas/CD95
deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS ONE 5:
e9070.
14. Xing J, Lv B, Xie C, Qu J, Lou H (2008) Liquid chromatography-tandem mass
spectrometry assay for the quantitation of plagiochin E and its main metabolite
plagiochin E glucuronides in rat plasma. J Pharm Biomed Anal 47: 949–953.
15. Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R (2010)
Chemoprevention of intestinal tumorigenesis in APC
min/+ mice by silibinin.
Cancer Res 70: 2368–2378.
16. Hu R, Khor TO, Shen G, Jeong WS, Hebbar V, et al. (2006) Cancer
chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a
natural product derived from cruciferous vegetable. Carcinogenesis 27:
2038–2046.
17. Shen G, Khor TO, Hu R, Yu S, Nair S, et al. (2007) Chemoprevention of
familial adenomatous polyposis by natural dietary compounds sulforaphane and
dibenzoylmethane alone and in combination in Apc
Min/+ mouse. Cancer Res 67:
9937–9944.
18. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, et al. (2010) ERK
activation drives intestinal tumorigenesis in Apc
min/+ mice. Nat Med 16:
665–670.
19. An YT, Zhao Z, Sheng YC, Min Y, Xia YY (2011) Therapeutic time window of
YGY-E neuroprotection of cerebral ischemic injury in rats. Drug Discov Ther 5:
76–83.
20. Liu J, Li X, Cheng YN, Cui SX, Chen MH, et al. (2007) Inhibition of human
gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a
precursor of 5-fluorouracil. Eur J Pharmacol 574: 1–7.
21. Liu J, Li X, Cheng YN, Cui SX, Chen MH, et al. (2008) Des-gamma-carboxy
prothrombin increases the expression of angiogenic factors in human
hepatocellular carcinoma cells. Life Sci 83: 815–820.
22. Seno H, Oshima M, Ishikawa TO, Oshima H, Takaku K, et al. (2002)
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogen-
esis in Apc(Delta716) mouse intestinal polyps. Cancer Res 62: 506–511.
23. Park EJ, Shin JH, Seo YS, Kim DW, Hong SY, et al. (2011) Gonadotropin-
releasing hormone-agonist induces apoptosis of human granulosa-luteal cells via
caspase-8, -9 and -3, and poly-(ADP-ribose)-polymerase cleavage. Biosci Trends
5: 120–128.
24. He H, Xia HH, Wang JD, Gu Q, Lin MC, et al. (2006) Inhibition of human
telomerase reverse transcriptase by nonsteroidal antiinflammatory drugs in colon
carcinoma. Cancer 106: 1243–1249.
25. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH (2010) Cyclooxygenase-2 in
tumorigenesis of gastrointestinal cancers: an update on the molecular
mechanisms. Cancer Lett 295: 7–16.
26. Asakawa Y, Toyota M, Tori M, Hashimoto T (2000) Chemical structures of
macrocyclic bis(bibenzyls) isolated from liverworts (Hepaticae). Spectroscopy 14:
149–175.
27. Shi YQ, Zhu CJ, Yuan HQ, Li BQ, Gao J, et al. (2009) Marchantin C, a novel
microtubule inhibitor from liverwort with anti-tumor activity both in vivo and in
vitro. Cancer Lett 276: 160–170.
28. Wu XZ, Cheng AX, Sun LM, Sun SJ, Lou HX (2009) Plagiochin E, an
antifungal bis(bibenzyl), exerts its antifungal activity through mitochondrial
dysfunction-induced reactive oxygen species accumulation in Candida albicans.
Biochim Biophys Acta 1790: 770–777.
29. Guillen-Ahlers H, Buechler SA, Suckow MA, Castellino FJ, Ploplis VA (2008)
Sulindac treatment alters collagen and matrilysin expression in adenomas of
Apc
Min/+ mice. Carcinogenesis 29: 1421–1427.
30. Fearnhead NS, Britton MP, Bodmer WF (2001) The ABC of APC. Hum Mol
Genet 10: 721–733.
Riccardin D Inhibits Intestinal Adenoma in Mice
PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e3324331. Greenspan EJ, Nichols FC, Rosenberg DW (2010) Molecular alterations
associated with sulindac-resistant colon tumors in Apc
Min/+ mice. Cancer Prev
Res (Phila) 3: 1187–1197.
32. Kuniyasu H, Luo Y, Fujii K, Sasahira T, Moriwaka Y, et al. (2010) CD10
enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect
of methionine-enkephalin in the liver. Gut 59: 348–356.
33. Mladenova D, Daniel JJ, Dahlstrom JE, Bean E, Gupta R, et al. (2011) The
NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic
in the proximal colon. Gut 60: 350–360.
34. Carothers AM, Davids JS, Damas BC, Bertagnolli MM (2010) Persistent
cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic
intestinal inflammation in the Min/+ mouse model of colon tumorigenesis.
Cancer Res 70: 4433–4442.
35. Kumar A, Takada Y, Boriek AM, Aggarwal BB (2004) Nuclear factor-kappaB:
its role in health and disease. J Mol Med 82: 434–448.
36. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K (2006) Role of
cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review
and report of personal experience. World J Gastroenterol 12: 1336–1345.
37. Axelsson H, Lo ¨nnroth C, Andersson M, Lundholm K (2010) Mechanisms
behind COX-1 and COX-2 inhibition of tumor growth in vivo. Int J Oncol 37:
1143–1152.
38. Wang D, Mann JR, DuBois RN (2004) WNT and cyclooxygenase-2 cross-talk
accelerates adenoma growth. Cell Cycle 3: 1512–1515.
39. Zak S, Treven J, Nash N, Gutierrez LS (2008) Lack of thrombospondin-1
increases angiogenesis in a model of chronic inflammatory bowel disease.
Int J Colorectal Dis 23: 297–304.
40. Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, et al. (2003) b-Catenin
regulates vascular endothelial growth factor expression in colon cancer. Cancer
Res 63: 3145–153.
Riccardin D Inhibits Intestinal Adenoma in Mice
PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e33243